Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 25: 1761-1765, 1979;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, W. J.
Right arrow Articles by Warnock, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, W. J.
Right arrow Articles by Warnock, L. G.

Clinical Chemistry, Vol 25, 1761-1765, Copyright © 1979 by American Association for Clinical Chemistry

Spurious hyperbilirubinemia in uremic patients on propranolol therapy

WJ Stone, TD McKinney and LG Warnock

Chronic, low-grade, unexplained increases of total serum bilirubin concentration were observed in 16 of 132 (12%) chronic dialysis patients. Cessation of antihypertensive medication in four patients resulted in disappearance of hyperbilirubinemia. Propranolol was the only antihypertensive drug common to all 16 patients. Daily dosage varied among the patients, but the mean dose was 308 mg (+/- 51 SEM). Serial determinations of sera from individual patients given different doses and from the group as a whole demonstrated a linear relationship between propranolol dose and apparent total serum bilirubin concentration with continuous-flow analysis. When serum specimens from uremic patients receiving propranolol were treated with diazotized fulfanilic acid and examined spectrophotometrically, an absorbance peak distinct from but overlapping that of bilirubin was consistently demonstrated. The material producing the peak disappeared when the drug was stopped, did not dialyze, and was not reproduced by the in vitro addition of propranolol to uremic serum. We postulate that a metabolite(s) of propranolol is retained in uremic serum and interferes with the bilirubin determination.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the American Association for Clinical Chemistry.